Etelcalcetide: What we know eight years since its approval
Introduction and objectives: The impact of etelcalcetide on patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT) has been studied since its introduction in 2016/2017. However, only a handful of studies reported clinically relevant outcomes. This narrative review aims t...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Espanhol |
| Vydáno: |
Elsevier
2025-02-01
|
| Edice: | Nefrología |
| Témata: | |
| On-line přístup: | http://www.sciencedirect.com/science/article/pii/S0211699524000900 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|